Serevent (salmeterol xinafoate)

January 23, 2003

Audience: Pulmonary specialists and other healthcare professionals

GlaxoSmithKline notified healthcare professionals of important new safety information on use of Serevent in patients with asthma. Recent findings from an interim analysis of a large Serevent safety study have prompted further review of the potential association between Serevent and rare, but potentially serious, respiratory adverse events.

[January 23, 2003 Letter - FDA] PDF Format
[January 23, 2003 Talk Paper - FDA]

View comments

Hide
(web1)